...刊奖 - Powered by SupeSite ，部分缓解（partial remission,PR）17例，稳定（no change,NC）3例，无进展（progressive disease，PD）病例。
基于4个网页-相关网页
无进展生存期 PFS ; Progression-Free Survival ; progression free survival ; progress free survival
无进展生存 PFS ; progression-free survival ; progress free sverial
无进展生存时间 PFS ; progression-free survival
毫无进展 get nowhere ; blank wall ; in circles ; getnowherewith
无进展生存率 PFS ; progression-free survival
一无进展 get nowhere
毫无进展的 gainless
中位无进展生存期 PFS ; MPFS ; progression-free survival
无进展的 moribund
在两项研究中，主要功效评估指标是无进展生存期。
In both studies, the primary efficacy endpoint was progression-free survival.
因此，替代终点如反应率和无进展生存率被普遍接受，尽管各方意识到风险所在。
Thus, surrogate endpoints like response rate and progression-free survival are commonly accepted, although all parties involved realize the risk involved.
药物联用的中值无进展存活期为11.8个月，是用单独紫杉醇获得的5.9个月的两倍。
The median progression-free survival period with the drug combination was 11.8 months, twice as long as the 5.9 months achieved with paclitaxel alone.
应用推荐